Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EIF4EBP1 | Q13541 | 5/20 | 0.46 |
| ▸ | UGT8 | Q16880 | 13/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | ASPH | Q12797 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21813966 | 0.84 | KDM4E (0.52) | EIF4EBP1UGT8KDM4E | |
| SCHEMBL21813874 | 0.84 | UGT8 (0.58) | UGT8 | |
| SCHEMBL30845442 | 0.84 | UGT8 (0.58) | UGT8 | |
| SCHEMBL28718650 | 0.80 | EIF4EBP1 (0.35) | EIF4EBP1 | |
| SCHEMBL28704856 | 0.69 | EIF4EBP1 (0.41) | EIF4EBP1 | |
| SCHEMBL31118733 | 0.69 | EIF4A1 (0.48) | KDM4E | |
| SCHEMBL21813614 | 0.68 | UGT8 (0.55) | UGT8 | |
| SCHEMBL30845434 | 0.68 | UGT8 (0.55) | UGT8 | |
| SCHEMBL2090729 | 0.67 | ALDH1A1 (0.49) | ASPH | |
| SCHEMBL1536029 | 0.67 | ASPH (0.53) | KDM4EASPH |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-113423711-B | Thieno [3,2-B ] pyridine derivatives as UDP glycosyltransferase inhibitors and methods of use thereof | 建新公司 | 2024-03-15 | — | — | CN | disclosed |
| US-20200102324-A1 | UDP GLYCOSYLTRANSFERASE INHIBITORS AND METHODS OF USE | GENZYME CORPORATION | 2020-04-02 | — | — | US | disclosed |
| US-20200102324-A1 | UDP GLYCOSYLTRANSFERASE INHIBITORS AND METHODS OF USE | GENZYME CORPORATION | 2020-04-02 | — | — | US | disclosed |
| US-20030055093-A1 | Acylated indanyl amines and their use as pharmaceuticals | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2003-03-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200102324-A1 | UDP GLYCOSYLTRANSFERASE INHIBITORS AND METHODS OF USE | MAN2B1, GAA, GBA1 | EIF4EBP1 2940/4885UGT8 74/4885KDM4E 647/4885 |
| US-20030055093-A1 | Acylated indanyl amines and their use as pharmaceuticals | EDNRA, VEGFA, EDNRB | EIF4EBP1 3480/4885UGT8 1908/4885KDM4E 569/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.